Search

Your search keyword '"Edward J. Wild"' showing total 117 results

Search Constraints

Start Over You searched for: "Edward J. Wild" Remove constraint "Edward J. Wild" Language english Remove constraint Language: english
117 results on '"Edward J. Wild"'

Search Results

1. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice

2. A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer’s disease

Catalog

Books, media, physical & digital resources

3. Lumbar puncture safety and tolerability in premanifest and manifest Huntington’s disease: a multi-analysis cross-sectional study

4. A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study

5. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease

6. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.

7. Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays.

8. Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease.

10. Estimating the causal effects of modifiable, non-genetic factors on Huntington Disease progression using propensity score weighting

11. Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntingtons disease: the prospective HD-CSF study

12. Brain-derived neurotrophic factor in patients with Huntington's disease.

13. Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes

14. Neurofilament light protein in blood predicts regional atrophy in Huntington disease

15. Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression

16. JAK/STAT Signalling in Huntington's Disease Immune Cells

17. Brain-derived neurotrophic factor in patients with Huntington's disease

18. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntingtons disease

20. Huntington's Disease Clinical Trials Update: September 2024.

21. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.

22. Poly ADP-ribose signaling is dysregulated in Huntington disease.

23. CSF neurofilament light chain profiling and quantitation in neurological diseases.

24. Huntington's Disease Clinical Trials Corner: March 2024.

25. Freesurfer Software Update Significantly Impacts Striatal Volumes in the Huntington's Disease Young Adult Study and Will Influence HD-ISS Staging.

28. Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?

29. A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer's disease.

30. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntingtons disease.

31. Huntington's Disease Clinical Trials Corner: August 2023.

32. Lumbar puncture safety and tolerability in premanifest and manifest Huntington's disease: a multi-analysis cross-sectional study.

33. Huntington's Disease Clinical Trials Corner: November 2022.

34. Research Reports on Huntington Disease from Queen Elizabeth University Hospital Provide New Insights (Comparative analysis of neurofilament light chain in Huntington's disease like 2 and Huntington's disease).

35. Natural history and burden of Huntington's disease in the UK: A population‐based cohort study.

36. Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children.

37. Huntington's Disease Clinical Trials Corner: April 2022.

38. Message From the Editors to Our Reviewers.

39. Safety and Feasibility of Research Lumbar Puncture in Huntington's Disease: The HDClarity Cohort and Bioresource.

40. Abstracts of the 28th Annual Meeting of the Huntington Study Group, November 4-6, 2021.

41. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.

42. Development of a targeted proteomic assay for the quantitation of neurofilament light in cerebrospinal fluid: Correlation with Simoa‐based quantitation across neurodegenerative diseases and centres.

43. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease.

44. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.

45. Neuropsychiatric comorbidities in Huntington's and Parkinson's Disease: A United States claims database analysis.

46. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease.

47. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.

49. Huntington's Disease Clinical Trials Corner: April 2020.

50. Characterizing White Matter in Huntington's Disease.